GAETANO FACCHINI
GAETANO FACCHINI
Director of Medical Oncology Unit - ASL Napoli 2 Nord - Pozzuoli-Ischia
Email verificata su aslnapoli2nord.it
Titolo
Citata da
Citata da
Anno
Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience.
F Diurno, FG Numis, G Porta, F Cirillo, S Maddaluno, A Ragozzino, ...
European review for medical and pharmacological sciences 24 (7), 4040-4047, 2020
2302020
Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients
A Ottaiano, R Franco, AA Talamanca, G Liguori, F Tatangelo, P Delrio, ...
Clinical cancer research 12 (9), 2795-2803, 2006
2282006
Percutaneous ethanol injection efficacy in the treatment of large symptomatic thyroid cystic nodules: ten-year follow-up of a large series
S Del Prete, M Caraglia, D Russo, G Vitale, G Giuberti, M Marra, ...
Thyroid 12 (9), 815-821, 2002
1242002
Epithelial-mesenchymal transition in prostate cancer: an overview
M Montanari, S Rossetti, C Cavaliere, C D'Aniello, MG Malzone, ...
Oncotarget 8 (21), 35376, 2017
1202017
Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naiveá…
KN Chi, A Protheroe, A RodrÝguez-AntolÝn, G Facchini, H Suttman, ...
The Lancet Oncology 19 (2), 194-206, 2018
972018
Chemotherapy in epithelial ovarian cancer
S Pignata, L Cannella, D Leopardo, C Pisano, GS Bruni, G Facchini
Cancer letters 303 (2), 73-83, 2011
952011
Concomitant CXCR4 and CXCR7 expression predicts poor prognosis in renal cancer
C D'alterio, C Consales, M Polimeno, R Franco, L Cindolo, L Portella, ...
Current cancer drug targets 10 (7), 772-781, 2010
952010
Systemic immune-inflammation index predicts the clinical outcome in patients with mCRPC treated with abiraterone
C Lolli, O Caffo, E Scarpi, M Aieta, V Conteduca, F Maines, E Bianchi, ...
Frontiers in pharmacology 7, 376, 2016
932016
Microbiota effects on cancer: from risks to therapies
D Rea, G Coppola, G Palma, A Barbieri, A Luciano, P Del Prete, ...
Oncotarget 9 (25), 17915, 2018
912018
Use of Complementary and Alternative Medicine (CAM) in cancer patients: An Italian multicenter survey
M Berretta, C Della Pepa, P Tralongo, A Fulvi, F Martellotta, A Lleshi, ...
Oncotarget 8 (15), 24401, 2017
912017
Phase I-II study of gemcitabine and carboplatin in stage IIIB-IV non–small-cell lung cancer
RV Iaffaioli, A Tortoriello, G Facchini, F Caponigro, M Gentile, N Marzano, ...
Journal of clinical oncology 17 (3), 921-921, 1999
841999
First-line treatment of advanced ovarian cancer: current research and perspectives
C Marchetti, C Pisano, G Facchini, GS Bruni, FP Magazzino, S Losito, ...
Expert review of anticancer therapy 10 (1), 47-60, 2010
832010
Clinical outcomes of castration-resistant prostate cancer treatments administered as third or fourth line following failure of docetaxel and other second-line treatmentá…
O Caffo, U De Giorgi, L Fratino, D Alesini, V Zagonel, G Facchini, ...
European urology 68 (1), 147-153, 2015
802015
Micrornas in prostate cancer: an overview
D Vanacore, M Boccellino, S Rossetti, C Cavaliere, C D'Aniello, ...
Oncotarget 8 (30), 50240, 2017
772017
Ovarian cancer standard of care: are there real alternatives?
C Della Pepa, G Tonini, C Pisano, M Di Napoli, SC Cecere, R Tambaro, ...
Chinese journal of cancer 34 (1), 17-27, 2015
772015
Angiogenesis inhibitors for the treatment of hepatocellular carcinoma
M Berretta, L Rinaldi, F Di Benedetto, A Lleshi, V De Re, G Facchini, ...
Frontiers in pharmacology 7, 428, 2016
572016
Follow-up with CA125 after primary therapy of advanced ovarian cancer: in favor of continuing to prescribe CA125 during follow-up
S Pignata, L Cannella, D Leopardo, GS Bruni, G Facchini, C Pisano
Annals of oncology 22, viii40-viii44, 2011
572011
Emerging strategies to strengthen the anti-tumour activity of type I interferons: overcoming survival pathways
M Caraglia, M Marra, P Tagliaferri, SWJ Lamberts, S Zappavigna, G Misso, ...
Current cancer drug targets 9 (5), 690-704, 2009
542009
New treatment approaches in renal cell carcinoma
G Facchini, F Perri, M Caraglia, C Pisano, S Striano, L Marra, F Fiore, ...
Anti-cancer drugs 20 (10), 893-900, 2009
532009
Serum and tissue markers in hepatocellular carcinoma and cholangiocarcinoma: clinical and prognostic implications
M Berretta, C Cavaliere, L Alessandrini, B Stanzione, G Facchini, ...
Oncotarget 8 (8), 14192, 2017
512017
Il sistema al momento non pu˛ eseguire l'operazione. Riprova pi¨ tardi.
Articoli 1–20